Ontology highlight
ABSTRACT:
SUBMITTER: Corbett KS
PROVIDER: S-EPMC7581537 | biostudies-literature | 2020 Oct
REPOSITORIES: biostudies-literature
Corbett Kizzmekia S KS Edwards Darin K DK Leist Sarah R SR Abiona Olubukola M OM Boyoglu-Barnum Seyhan S Gillespie Rebecca A RA Himansu Sunny S Schäfer Alexandra A Ziwawo Cynthia T CT DiPiazza Anthony T AT Dinnon Kenneth H KH Elbashir Sayda M SM Shaw Christine A CA Woods Angela A Fritch Ethan J EJ Martinez David R DR Bock Kevin W KW Minai Mahnaz M Nagata Bianca M BM Hutchinson Geoffrey B GB Wu Kai K Henry Carole C Bahl Kapil K Garcia-Dominguez Dario D Ma LingZhi L Renzi Isabella I Kong Wing-Pui WP Schmidt Stephen D SD Wang Lingshu L Zhang Yi Y Phung Emily E Chang Lauren A LA Loomis Rebecca J RJ Altaras Nedim Emil NE Narayanan Elisabeth E Metkar Mihir M Presnyak Vlad V Liu Cuiping C Louder Mark K MK Shi Wei W Leung Kwanyee K Yang Eun Sung ES West Ande A Gully Kendra L KL Stevens Laura J LJ Wang Nianshuang N Wrapp Daniel D Doria-Rose Nicole A NA Stewart-Jones Guillaume G Bennett Hamilton H Alvarado Gabriela S GS Nason Martha C MC Ruckwardt Tracy J TJ McLellan Jason S JS Denison Mark R MR Chappell James D JD Moore Ian N IN Morabito Kaitlyn M KM Mascola John R JR Baric Ralph S RS Carfi Andrea A Graham Barney S BS
Nature 20200805 7830
A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to control the coronavirus disease 2019 (COVID-19) global pandemic. Structural studies have led to the development of mutations that stabilize Betacoronavirus spike proteins in the prefusion state, improving their expression and increasing immunogenicity<sup>1</sup>. This principle has been applied to design mRNA-1273, an mRNA vaccine that encodes a SARS-CoV-2 spike protein that is stabilized in the prefusion co ...[more]